Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 1, 2007, Pages 83-93

  Ekshyyan, Viktoriya P ^a   Hebert, Valeria Y ^a   Khandelwal, Alok ^a   Dugas, Tammy R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Estrogen receptors; Proliferation; Resveratrol; Tetrahydrobiopterin; Vascular smooth muscle cells

Indexed keywords

7 NITROINDAZOLE; ANTIESTROGEN; BROMINE DERIVATIVE; DIHYDROBROMIDE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INDUCIBLE NITRIC OXIDE SYNTHASE; N5 (1 IMINOETHYL)ORNITHINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OXYGENASE INHIBITOR; RESVERATROL; S,S' 1,4 PHENYLENE BIS(1,2 ETHANEDIYL)BIS ISOTHIOUREA; TETRAHYDROBIOPTERIN; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; IC 50; MALE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIOXIDANTS; AORTA; APOPTOSIS; BIOPTERIN; CELL CYCLE; CELL PROLIFERATION; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANOSINE TRIPHOSPHATE; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; STILBENES;

EID: 34547674896     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318059ae80     Document Type: Article

References (64)

1. Ramos KS, Bowes RC 3rd, Ou X, et al. Responses of vascular smooth muscle cells to toxic insult: cellular and molecular perspectives for environmental toxicants. J Toxicol Environ Health. 1994;43:419-440.
2. Buemi M, Marino D, Di Pasquale G, et al. Effects of homocysteine on proliferation, necrosis, and apoptosis of vascular smooth muscle cells in culture and influence of folic acid. Thromb Res. 2001;104:207-213.
3. Bellosta S, Arnaboldi L, Gerosa L, et al. Statins effect on smooth muscle cell proliferation. Semin Vasc Med. 2004;4:347-356.
4. Andres V, Castro C. Antiproliferative strategies for the treatment of vascular proliferative disease. Curr Vasc Pharmacol. 2003;1:85-98.
5. Ducimetie're P, Richard JL, Cambien F, et al. Coronary heart disease in middle-aged Frenchmen. Comparisons between Paris Prospective Study, Seven Countries Study, and Pooling Project. Lancet. 1980;1:1346-1350.
6. Klurfeld DM, Kritchevsky D. Differential effects of alcoholic beverages on experimental atherosclerosis in rabbits. Exp Mol Pathol. 1981;34:62-71.
7. Wu JM, Wang ZR, Hsieh TC, et al. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review). Int J Mol Med. 2001;8:3-17.
8. Martinez-Ortega MV, Carcia-Parrilla MC, Troncoso AM. Resveratrol content in wines and musts from the south of Spain. Nahrung. 2000;44:253-256.
9. Bertelli AA, Giovannini L, Stradi R, et al. Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res. 1998;24:51-55.
10. Bertelli A, Bertelli AA, Gozzini A, et al. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res. 1998;24:133-138.
11. Zou J, Huang Y, Cao K, et al. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci. 2000;68:153-163.
12. El-Mowafy AM, White RE. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett. 1999;451:63-67.
13. Zou J, Huang Y, Chen Q, et al. Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells. Int J Oncol. 1999;15:647-651.
14. Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun. 2000;274:61-67.
15. Di Castelnuovo A, Rotondo S, Iacoviello L, et al. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation. 2002;105:2836-2844.
16. de Gaetano G, Di Castelnuovo A, Donati MB, et al. The mediterranean lecture: wine and thrombosis-from epidemiology to physiology and back. Pathophysiol Haemost Thromb. 2003-2004;33:466-471.
17. Hayashi T, Yamada K, Esaki T, et al. Physiological concentrations of 17beta-estradiol inhibit the synthesis of nitric oxide synthase in macrophages via a receptor-mediated system. J Cardiovasc Pharmacol. 1998;31:292-298.
18. Maggi A, Cignarella A, Brusadelli A, et al. Diabetes undermines estrogen control of inducible nitric oxide synthase function in rat aortic smooth muscle cells through overexpression of estrogen receptor-beta. Circulation. 2003;108:211-217.
19. Mershon JL, Baker RS, Clark KE. Estrogen increases iNOS expression in the ovine coronary artery. Am J Physiol Heart Circ Physiol. 2002;283:H1169-H1180.
20. Nuedling S, Kahlert S, Loebbert K, et al. 17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc Res. 1999;43:666-674.
21. Jeremy JY, Rowe D, Emsley AM, et al. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res. 1999;43:580-594.
22. Sarkar R, Webb RC. Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal. J Vasc Res. 1998;35:135-142.
23. Dugas TR, Hebert VY, Hennard KL, et al. Vascular medial hyperplasia following chronic, intermittent exposure to 4,4′-methylenedianiline. Cardiovasc Toxicol. 2004;4:85-96.
24. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867-3873.
25. Huong PL, Kolk AH, Eggelte TA, et al. Measurement of antigen specific lymphocyte proliferation using 5-bromo-deoxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation. J Immunol Meth. 1991;140:243-248.
26. Pias EK, Ekshyyan OY, Rhoads CA, et al. Differential effects of superoxide dismutase isoform expression on hydroperoxide-induced apoptosis in PC-12 cells. J Biol Chem. 2003;278:13294-13301.
27. Stoessel S, Leclerca G. Competitive binding assay for estrogen receptor in monolayer culture: measure of receptor activation potency. J Steroid Bichem. 1986;25:677-682.
28. Rees DD, Palmer RM, Schulz R, et al. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990;101:746-752.
29. Schmidt K, Mayer B. Assay of tissue activity of nitric oxide synthase. In: Maines MD, ed. Current Protocols in Toxicology. Hoboken, NJ: John Wiley; 1999.
30. Moore WM, Webber RK, Jerome GM, et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem. 1994;37:3886-3888.
31. Garvey EP, Oplinger JA, Tanoury GJ, et al. Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J Biol Chem. 1994;269:26669-26676.
32. Babbedge RC, Bland-Ward PA, Hart SL, et al. Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles. Br J Pharmacol. 1993;110:225-228.
33. Howells DW, Smith I, Hyland K. Estimation of tetrahydrobiopterin and other pterins in cerebrospinal fluid using reversed-phase high-performance liquid chromatography with electrochemical and fluorescence detection. J Chromatogr. 1986;381:285-294.
34. Mnjoyan ZH, Fujise K. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/CIP1) pathway. Biochem Biophys Res Commun. 2003;311:546-552.
35. Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol. 2002;188:125-140.
36. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367:595-604.
37. Gehm BD, McAndrews JM, Chien PY, et al. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA. 1997;94:14138-14143.
38. Buchwalow IB, Podzuweit T, Bocker W, et al. Vascular smooth muscle and nitric oxide synthase. FASEB J. 2002;16:500-508.
39. Babal P, Pechanova O, Bernatova I, et al. Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histol Histopathol. 1997;12:623-629.
40. Darblade B, Pendaries C, Krust A, et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res. 2002;90:413-419.
41. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol. 2002;90:3F-6F.
42. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol. 2002;64:749-774.
43. Xu R, Morales JA, Muniyappa R, et al. Interleukin-1beta-induced nitric oxide production in rat aortic endothelial cells: inhibition by estradiol in normal and high glucose cultures. Life Sci. 1999;64:2451-2462.
44. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106:1652-1658.
45. Cho DI, Koo NY, Chung WJ, et al. Effects of resveratrol-related hydroxystilbenes on the nitric oxide production in macrophage cells: structural requirements and mechanism of action. Life Sci. 2002;71:2071-2082.
46. Zou JG, Wang ZR, Huang YZ, et al. Effect of red wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med. 2003;11:317-320.
47. Kavdia M, Popel AS. Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure. J Appl Physiol. 2004;97:293-301.
48. El-Gayar S, Thuring-Nahler H, Pfeilschifter J, et al. Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages. J Immunol. 2003;171:4561-4568.
49. Nagao K, Takenaka S, Yamaji R, et al. Nitric oxide synthase induction, cGMP elevation, and biopterin synthesis in vascular smooth muscle cells stimulated with interleukin-1beta in hypoxia. J Biochem (Tokyo). 2003;133:501-505.
50. Galijasevic S, Saed GM, Diamond MP, et al. Myeloperoxidase upregulates the catalytic activity of inducible nitric oxide synthase by preventing nitric oxide feedback inhibition. Proc Natl Acad Sci USA. 2003;100:14766-14771.
51. Daniliuc S, Bitterman H, Rahat MA, et al. Hypoxia inactivates inducible nitric oxide synthase in mouse macrophages by disrupting its interaction with alpha-actinin 4. J Immunol. 2003;171:3225-3232.
52. Kwon NS, Nathan CF, Stuehr DJ. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem. 1989;264:20496-20501.
53. Gross SS, Levi R. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem. 1992;267:25722-25729.
54. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol. 1995;57:707-736.
55. Crane BR, Arvai AS, Ghosh DK, et al. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science. 1998;279:2121-2126.
56. Ghosh DK, Abu-Soud HM, Stuehr DJ. Domains of macrophage N(O) synthase have divergent roles in forming and stabilizing the active dimeric enzyme. Biochemistry. 1996;35:1444-1449.
57. Craig DH, Chapman SK, Daff S. Calmodulin activates electron transfer through neuronal nitric-oxide synthase reductase domain by releasing an NADPH-dependent conformational lock. J Biol Chem. 2002;277:33987-33994.
58. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol. 1996;27:363-366.
59. Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol. 1997;37:339-359.
60. Sengupta R, Sahoo R, Ray SS, et al. Dissociation and unfolding of inducible nitric oxide synthase oxygenase domain identifies structural role of tetrahydrobiopterin in modulating the heme environment. Mol Cell Biochem. 2006;284:117-126.
61. Serova LI, Maharjan S, Huang A, et al. Response of tyrosine hydroxylase and GTP cyclohydrolase I gene expression to estrogen in brain catecholaminergic regions varies with mode of administration. Brain Res. 2004;1015:1-8.
62. Lam KK, Ho ST, Yen MH. Tetrahydrobiopterin improves vascular endothelial function in ovariectomized rats. J Biomed Sci. 2002;9:119-125.
63. Nichol CA, Lee CL, Edelstein MP, et al. Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. Proc Natl Acad Sci USA. 1983;80:1546-1550.
64. Serova LI, Filipenko M, Schilt N, et al. Estrogen-triggered activation of GTP cyclohydrolase 1 gene expression: Role of estrogen receptor subtypes and interaction with cyclic AMP. Neuroscience. 2006;140:1253-1263.